Noha A Ghallab1, Olfat G Shaker2. 1. Department of Oral Medicine, Periodontology and Diagnosis, Faculty of Oral and Dental Medicine, Cairo University, 43 Zahraa street, Dokki, Guiza, Egypt. noha26@yahoo.com. 2. Department of Medical Biochemistry, Faculty of Medicine, Cairo University, Guiza, Egypt.
Abstract
OBJECTIVE: The objective of this study was to investigate serum and salivary levels of chemerin and MMP-9 as early diagnostic biomarkers for patients with oral premalignant lesions (OPMLs) and oral squamous cell carcinoma (OSCC). METHODS: This study included 45 individuals; 15 healthy control, 15 patients with OPMLs, and 15 patients with early stage OSCC. Chemerin and MMP-9 were determined in serum and saliva samples utilizing enzyme-linked immunosorbent assays. RESULTS: Serum and salivary levels of chemerin and MMP-9 in patients with OSCC were significantly higher than OPMLs and control group. Patients with OPMLs showed also elevated profiles for serum and salivary chemerin and MMP-9 compared to control group. Receiver operator characteristic curve analysis revealed that all tested biomarkers have 100 % sensitivity and 100 % specificity with area under the curve (AUC) of 1.00 in detecting early stage OSCC and OPMLs. In distinguishing OSCC from OPMLs, salivary MMP-9, serum chemerin, and salivary chemerin showed AUC of 0.99, 0.92, and 0.88, respectively, showing higher sensitivity and specificity compared with serum MMP-9 (AUC; 0.6) which failed to differentiate between the two conditions. CONCLUSION: Chemerin and MMP-9 might be considered as salivary diagnostic biomarkers for OPMLs and early detection of OSCC and also for detecting early cancerization of OPMLs. CLINICAL RELEVANCE: This research implied that salivary chemerin was a novel diagnostic factor for patients with OPML and early stage OSCC patients, and chemerin could be a new therapeutic target for regulating cancer angiogenesis and blocking malignization of OPMLs.
OBJECTIVE: The objective of this study was to investigate serum and salivary levels of chemerin and MMP-9 as early diagnostic biomarkers for patients with oral premalignant lesions (OPMLs) and oral squamous cell carcinoma (OSCC). METHODS: This study included 45 individuals; 15 healthy control, 15 patients with OPMLs, and 15 patients with early stage OSCC. Chemerin and MMP-9 were determined in serum and saliva samples utilizing enzyme-linked immunosorbent assays. RESULTS: Serum and salivary levels of chemerin and MMP-9 in patients with OSCC were significantly higher than OPMLs and control group. Patients with OPMLs showed also elevated profiles for serum and salivary chemerin and MMP-9 compared to control group. Receiver operator characteristic curve analysis revealed that all tested biomarkers have 100 % sensitivity and 100 % specificity with area under the curve (AUC) of 1.00 in detecting early stage OSCC and OPMLs. In distinguishing OSCC from OPMLs, salivary MMP-9, serum chemerin, and salivary chemerin showed AUC of 0.99, 0.92, and 0.88, respectively, showing higher sensitivity and specificity compared with serum MMP-9 (AUC; 0.6) which failed to differentiate between the two conditions. CONCLUSION:Chemerin and MMP-9 might be considered as salivary diagnostic biomarkers for OPMLs and early detection of OSCC and also for detecting early cancerization of OPMLs. CLINICAL RELEVANCE: This research implied that salivary chemerin was a novel diagnostic factor for patients with OPML and early stage OSCC patients, and chemerin could be a new therapeutic target for regulating cancer angiogenesis and blocking malignization of OPMLs.
Authors: L S Monteiro; M L Delgado; S Ricardo; B do Amaral; F Salazar; J J Pacheco; C A Lopes; H Bousbaa; S Warnakulasuryia Journal: Oral Dis Date: 2016-03-07 Impact factor: 3.511
Authors: Kiymet Bozaoglu; Joanne E Curran; Claire J Stocker; Mohamed S Zaibi; David Segal; Nicky Konstantopoulos; Shona Morrison; Melanie Carless; Thomas D Dyer; Shelley A Cole; Harald H H Goring; Eric K Moses; Ken Walder; Michael A Cawthorne; John Blangero; Jeremy B M Jowett Journal: J Clin Endocrinol Metab Date: 2010-03-17 Impact factor: 5.958
Authors: Russell K Pachynski; Brian A Zabel; Holbrook E Kohrt; Nicole M Tejeda; Justin Monnier; Christina D Swanson; Alison K Holzer; Andrew J Gentles; Gizette V Sperinde; Abdolhossein Edalati; Husein A Hadeiba; Ash A Alizadeh; Eugene C Butcher Journal: J Exp Med Date: 2012-07-02 Impact factor: 14.307
Authors: K Hema Shree; Pratibha Ramani; Herald Sherlin; Gheena Sukumaran; Gifrrina Jeyaraj; K R Don; Archana Santhanam; Abilasha Ramasubramanian; R Sundar Journal: Pathol Oncol Res Date: 2019-02-02 Impact factor: 3.201